Parexel has extended its partnership with decentralized trials technology specialist Medidata.
Clare Grace, Parexel’s chief patient offer, said the extension is part of a wider effort to “enhance the clinical trial experience and make participation more accessible to everyone.”
She said, “Medidata’s DCT technologies further support our efforts in a market where nearly 75% of proposals include at least a hybrid trial model. We’re pleased to partner with them as we continue to expand our offerings in this area.”
This was echoed by Anthony Costello, patient cloud CEO at Medidata, who cited the deal alongside the surge in interest in remote clinical trials prompted by the pandemic as key.
“The COVID-19 pandemic showed us that we can leverage DCT technologies to expedite and enhance the entire clinical trials process.
“The relationship with Parexel represents an enormous opportunity to forever redefine the patient experience and development timelines for the development of new medicines and vaccines.”
The move builds on the accord the firms set up in 2007 which saw the contract research organization (CRO) start providing Medidata’s electronic clinical data capture (EDC), remote trial management and reporting tools to customers.
The agreement is the second decentralized trial focused move Parexel has made since it was acquired by private equity investors Goldman Sachs and EQT last year.
In April the firm teamed up with Veeva Systems, a developer of clinical trial and data management technologies.
At the time Veeva said Parexel would have access and provide input into its clinical products, including innovations to support sites and patients in decentralized clinical trials (DCT), risk-based quality management (RBQM), and community-based sites.
For Medidata the extension comes just weeks after the expansion of its accord with Circuit Clinical, a specialist CRO that has created a database of more than 2.5 million participants who may qualify for clinical trials.
It also follows a few months after Labcorp selected Medidata’s technology to expand its decentralized clinical trial offering.
Image: Stock Photo Secrets